In the study by Herbst et al. [50], PD-L1 expression by tumor-infiltrating immune cells, but not by tumor cells showed an association with the response to atezolizumab (anti-PD-L1) treatment in a mixed cohort of different cancer and in the subgroup of NSCLC. This evidence concerns the gene CD274 and neoplasm.